Logo (Paclitaxel 01)
Paclitaxel Injection, Solution
Product Images NDC 61703-342
20 FDA label images from Hospira, Inc. · Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 20 technical images submitted to the FDA as part of the official labeling for Paclitaxel (NDC 61703-342). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Hospira, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Paclitaxel Structural Formula (Paclitaxel 01a)
Chemical structure of paclitaxel showing its complex multi-ring structure, including aromatic phenyl groups and multiple ester and hydroxyl functional groups.*
Figure 1. Survival: Cc Versus Tc (intergroup) (Paclitaxel 02)
A survival curve chart depicting the proportion surviving over time in years, comparing two groups labeled Cc and Tc. The graph includes numbers at risk at yearly intervals and a summary inset with sample sizes, number of events, and hazard ratio (HR) with 95% confidence interval (CI) for the groups.*
Figure 2. Survival: Cc Versus Tc (gog-111) (Paclitaxel 03)
A Kaplan-Meier survival curve chart showing the proportion surviving over a 5-year period for two groups labeled Cc and Tc. The vertical axis represents proportion surviving from 0 to 1, and the horizontal axis represents years from 0 to 5. The chart includes a table with sample sizes, number of events, and hazard ratio with 95% confidence interval comparing the two groups.*
Figure 3. Disease-free Survival: Ac Versus Ac+t (Paclitaxel 04)
A Kaplan-Meier survival curve graph showing the proportion of patients disease free over a period of 4 years. Two treatment groups are compared: AC alone and AC plus T, with the AC+T group showing a higher proportion disease free. The graph includes number at risk counts at yearly intervals and a hazard ratio inset with confidence intervals comparing the two groups.*
Figure 4. Survival: Ac Versus Ac+t (Paclitaxel 05)
A survival curve chart showing the proportion of patients surviving over a period of 4 years. Two treatment groups are compared: AC and AC+T, with survival proportion on the vertical axis and years on the horizontal axis. A table within the chart provides sample sizes, number of events, and hazard ratio with confidence interval for both groups.*
Figure 5. Disease-free Survival: Receptor Status Negative/unknown Ac Versus Ac+t (Paclitaxel 06)
A Kaplan-Meier survival curve graph displaying the proportion of patients disease-free over a period of four years. Two treatment groups are compared: AC alone and AC combined with T (AC+T). The graph includes numbers at risk at various times and hazard ratio data with confidence intervals for disease-free survival outcomes.*
Figure 6. Disease-free Survival: Receptor Status Positive Ac Versus Ac+t (Paclitaxel 07)
A Kaplan-Meier survival curve chart depicting the proportion of disease-free patients over a 4-year period for two groups labeled AC and AC+T. The y-axis represents the proportion disease-free (0 to 1), and the x-axis represents time in years (0 to 4). Included is a table showing the number of patients, number of events, hazard ratio (HR), and 95% confidence interval (CI) for each group, along with the number of patients at risk at various time points.*
Figure 7. Disease-free Survival: Premonopausal Ac Versus Ac+t (Paclitaxel 08)
A Kaplan-Meier survival curve graph showing the proportion of patients disease-free over four years for two treatment groups, AC and AC+T. The graph plots years on the x-axis and proportion disease-free on the y-axis. Data includes number of patients, events, hazard ratio with confidence interval, and number at risk for each group.*
Figure 8. Disease-free Survival: Postmenopausal Ac Versus Ac+t (Paclitaxel 09)
A Kaplan-Meier survival curve showing the proportion of patients disease free over a period of 4 years. Two groups are compared: AC and AC+T. The graph includes a table with sample size, number of events, hazard ratio (HR), and 95% confidence interval (CI) for both groups, as well as numbers at risk at various time points.*
Logo (Paclitaxel 10)
Logo (Paclitaxel 11)
Principal Display Panel (5 mL Vial Label)
Label for Paclitaxel Injection, USP 30 mg/5 mL (6 mg/mL) intravenous injection solution. The 5 mL multiple dose vial is sterile and labeled with warnings including "Dilution Required Prior to IV Infusion" and "Cytotoxic Agent." The product is distributed by Hospira, Inc., Lake Forest, IL, USA.*
Principal Display Panel (5 mL Vial Carton)
Packaging label for Paclitaxel Injection, USP, 30 mg/5 mL (6 mg/mL) sterile intravenous injection by Hospira, Inc. The label includes warnings such as dilution required prior to IV infusion and indicates the vial is a multiple dose. It also marks the product as a cytotoxic agent and shows the NDC number 61703-342-09.*
Principal Display Panel (16.7 mL Vial Label)
Paclitaxel Injection, USP 100 mg per 16.7 mL (6 mg/mL) injection solution vial label from Hospira, Inc. The label states it is a sterile, multiple dose vial requiring dilution prior to intravenous infusion, with a caution for cytotoxic agent handling. The vial volume is 16.7 mL.*
Principal Display Panel (16.7 mL Vial Carton)
The packaging label for Paclitaxel Injection, USP 100 mg/16.7 mL (6 mg/mL) sterile intravenous solution by Hospira, Inc. The label includes dosage details, storage instructions, a barcode, and warnings such as "Cytotoxic Agent" and dilution required prior to IV infusion. The product is distributed by Hospira, Inc. and made in Canada.*
Principal Display Panel (50 mL Vial Label)
Label for Paclitaxel Injection USP 300 mg/50 mL (6 mg/mL) intravenous injection solution in a 50 mL vial. The label includes a caution that dilution is required prior to IV infusion and states it is a multiple dose vial and cytotoxic agent. The label also lists inactive ingredients and storage instructions. Manufactured by Hospira, Inc.*
Principal Display Panel (50 mL Vial Carton)
Paclitaxel Injection, USP 300 mg/50 mL (6 mg/mL) vial label from Hospira, Inc. The label includes dosage strength, vial size (50 mL), and administration route (intravenous). It highlights the formulation contains 6 mg Paclitaxel per mL with other ingredients and has warnings such as dilution required prior to IV infusion. The label also identifies the product as a cytotoxic agent and includes manufacturer and storage information.*
Principal Display Panel (5 mL Vial Label)
Label for Paclitaxel Injection, USP 30 mg/5 mL (6 mg/mL) sterile solution for intravenous use. The 5 mL vial label includes a caution that dilution is required prior to IV infusion and indicates it is a hazardous drug. Ingredients per mL include 6 mg paclitaxel and 527 mg polyoxy35 castor oil, along with alcohol, dehydrated alcohol, and citric acid. The product is distributed by Hospira, Inc. in Lake Forest, IL, USA. Storage instructions specify protecting from light and storing between 20° to 25°C (68° to 77°F).*
Principal Display Panel (5 mL Vial Carton)
Packaging label for Paclitaxel Injection, USP sterile solution, 30 mg/5 mL (6 mg/mL), multiple dose vial. The label shows the vial contents and dosage strength, with warnings including "Hazardous Drug" and "Caution: Dilution Required Prior to IV Infusion." The manufacturer is Hospira, Inc. The label also includes barcode and NDC 61703-015-04 information.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
